SAN DIEGO--(BUSINESS WIRE)--KFx Medical Corporation announced that the United States District Court ruled in KFx’s favor on two summary judgment motions in KFx’s pending patent infringement case against Arthrex.
First, the Court denied Arthrex’s motion for summary judgment. Arthrex had moved for summary judgment for patent invalidity based upon obviousness and for non-infringement on two separate grounds. In denying Arthrex’s motion, the Court ruled in KFx’s favor on all three summary judgment theories.
Second, the Court granted KFx’s motion for summary judgment thereby dismissing Arthrex’s defense which claimed two of the KFx patents were unenforceable based upon alleged inequitable conduct during patent procurement.
On August 1, 2011, KFx filed the complaint against Arthrex alleging claims of induced and contributory infringement of United States Patent Number 7,585,311 covering knotless double row repair of the rotator cuff. Over 400,000 rotator cuff surgeries are performed each year in the United States. Since that time KFx has been awarded an additional three patents covering variations of knotless double row repair, two of which were added to the suit versus Arthrex (United States Patent Numbers 8,100,942 and 8,109,969).
“We are pleased with our continued progress in the case and look forward to resolution during the trial in August, 2013,” indicated Tate Scott, president and CEO of KFX.
About KFx Medical Corporation
Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded in 2003 to develop products for tissue fixation in a variety of orthopedic surgical procedures performed on the shoulder, knee, foot, and ankle. KFx provides simple systems for orthopedic surgeons focused on sports medicine. The new AppianFx line of implants from KFx reattach tissue to and in bone in shoulder, knee, foot and ankle procedures which combined exceed well over 1 million annual surgical procedures in the United States. Product offerings include those that directly place and secure tissue into bone both with and without the use of sutures. The company is privately held — Investors include Alloy Ventures, Charter Life Sciences, Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.
